Forsta AP Fonden Takes Position in Insmed, Inc. $INSM

Forsta AP Fonden acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 45,100 shares of the biopharmaceutical company’s stock, valued at approximately $7,849,000.

A number of other hedge funds have also made changes to their positions in the stock. CIBC Private Wealth Group LLC grew its position in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares in the last quarter. Kingsview Wealth Management LLC grew its position in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares in the last quarter. Choreo LLC grew its position in shares of Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 69 shares in the last quarter. Finally, ORG Partners LLC grew its position in shares of Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 74 shares in the last quarter.

Insider Activity

In other news, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 156,643 shares of company stock valued at $24,513,766. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INSM shares. Stifel Nicolaus raised their price target on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Barclays raised their price target on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Mizuho lifted their price objective on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Finally, Leerink Partners lifted their price objective on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $210.95.

Insmed Stock Performance

Insmed stock opened at $106.03 on Tuesday. The company has a market cap of $22.98 billion, a PE ratio of -18.44 and a beta of 0.79. The company has a fifty day moving average price of $133.66 and a two-hundred day moving average price of $157.25. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a 12 month low of $69.59 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the company posted ($1.42) earnings per share. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. Research analysts expect that Insmed, Inc. will post -2.52 earnings per share for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.